Evaluation of two insulin assays in insulin resistance syndrome (syndrome X). 1994

S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7873.

Recent data suggest that proinsulin is associated with cardiovascular risk factors in nondiabetic and diabetic subjects. Since most conventional insulin assays cross-react with proinsulin, it has been suggested that the associations of insulin concentrations with dyslipidemia and hypertension could actually reflect associations with proinsulin. We examined these associations by using both a conventional immunoreactive insulin assay and a specific Linco insulin assay that does not cross-react with proinsulin in 623 nondiabetic and in 180 non-insulin-dependent diabetic subjects who participated in the San Antonio Heart Study, a population-based study of diabetes and cardiovascular disease. Both the immunoreactive insulin assay and the specific Linco insulin assay were equally correlated with cardiovascular risk factors in nondiabetic subjects. Insulin concentrations were moderately correlated with high triglyceride and low high-density lipoprotein cholesterol levels and were weakly correlated with increased blood pressure. In diabetic subjects there were only weak associations between insulin and cardiovascular risk factors using either assay. We conclude that the association of insulin concentrations with cardiovascular risk factors is not a function of using insulin assays that cross-react with proinsulin and that for epidemiological studies of cardiovascular risk factors, conventional immunoreactive insulin assays are as good as the newer specific insulin assays.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D008800 Mexico A country in NORTH AMERICA, bordering the Caribbean Sea and the Gulf of Mexico, between BELIZE and the UNITED STATES, and bordering the North Pacific Ocean, between Guatemala and the UNITED STATES.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006630 Hispanic or Latino A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race (https://www.federalregister.gov/documents/1997/10/30/97-28653/revisions-to-the-standards-for-the-classification-of-federal-data-on-race-and-ethnicity). In the United States it is used for classification of federal government data on race and ethnicity. Race and ethnicity terms are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. Cuban Americans,Hispanic Americans,Latin Americans, US,Latinas,Latinos,Latinx,Puerto Ricans,Spanish Americans,Hispanics,American, Hispanic,American, US Latin,Cuban American,Hispanic American,Hispanic or Latinos,Latin American, US,Latina,Latino,Puerto Rican,Spanish American,US Latin American,US Latin Americans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
August 1993, Lancet (London, England),
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
August 1993, Lancet (London, England),
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
August 1993, Lancet (London, England),
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
September 2001, The Journal of the Association of Physicians of India,
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
January 1997, Clinical and experimental pharmacology & physiology,
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
March 2000, European journal of clinical nutrition,
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
May 1999, Zhonghua nei ke za zhi,
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
July 1993, Lancet (London, England),
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
January 2007, Vojnosanitetski pregled,
S M Haffner, and L Mykkänen, and R A Valdez, and M P Stern
June 1992, Diabetes,
Copied contents to your clipboard!